1. Home
  2. ORIC

as 10-30-2025 9:34am EST

$
-
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

Founded: 2014 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 1.1B IPO Year: 2020
Target Price: $16.57 AVG Volume (30 days): 1.5M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.89 EPS Growth: N/A
52 Week Low/High: $3.90 - $14.93 Next Earning Date: 11-06-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Stock Insider Trading Activity of Oric Pharmaceuticals Inc. (ORIC)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Chacko Jacob ORIC PRESIDENT AND CEO Oct 6 '25 Sell $12.32 37,461 $461,519.52 531,419
Piscitelli Dominic ORIC Chief Financial Officer Oct 6 '25 Sell $14.52 11,000 $159,718.90 48,317
Chacko Jacob ORIC PRESIDENT AND CEO Oct 1 '25 Sell $12.05 53,001 $638,805.15 531,419
Chacko Jacob ORIC PRESIDENT AND CEO Sep 30 '25 Sell $12.01 34,538 $414,749.57 531,419
Chacko Jacob ORIC PRESIDENT AND CEO Sep 22 '25 Sell $10.80 125,000 $1,349,937.50 531,419

Share on Social Networks: